View this email in your browser



VALIDATING DIAGNOSTICS TO COMBAT ANTIMICROBIAL RESISTANCE BY OPTIMISING ANTIBIOTIC USE

WWW.VALUE-DX.EU

NEWSLETTER NOVEMBER 2022


VALUE-Dx WAAW 2022 campaign

Like every year, VALUE-Dx is celebrating the World Antibiotic Awareness Week (WAAW), from 18 until 24 November. This year's theme is 'Preventing Antimicrobial Resistance Together'. VALUE-Dx contributes to the fight against AMR by validating diagnostics and optimising antibiotic use. As healthcare professionals, it's vital to understand the responsibility that comes with prescribing antibiotics. <u>Discover more.</u>



POC diagnostics for infection management

For the WAAW 2022, we created an infographic highlighting the role of point-ofcare testing (POCT). During the COVID-19 pandemic, it became clear that POCT plays an important part in guiding patient management. It can be a powerful tool in combatting AMR by preventing unnecessary usage of antibiotics. <u>Read more.</u> Subscribe



Interview with PhD student Juan Pablo Rodriguez Ruiz



Read our interview with Juan Pablo Rodriguez Ruiz, a 27-year-old PhD student at <u>the</u> <u>Laboratory of Medical Microbiology</u> of the University of Antwerp. He studies the microbiome of patients suffering from Respiratory Tract Infections and the effect of antibiotic intake in these patients within the VALUE-Dx project. In the interview, Juan Pablo discusses his work with Work Package 2 within Value-Dx, his future tasks and more. <u>Read more.</u>

The effect of diagnostic testing on antibiotics prescriptions

In August 2022, VALUE-Dx published a new study in the European Journal of Health Economics titled 'Does diagnostic testing always decrease antibiotics prescriptions?'. The conclusion of this scientific paper is that we



should be very careful when we assert that point-of-care diagnostic testing (POCT) reduces antibiotics prescriptions as there are situations in which the opposite effect occurs. <u>Read more.</u>

• ECRAID-Base WP meeting, 30 November - 01 December, Verona (Italy)



Copyright © 2022 VALUE-Dx, All rights reserved.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is: value_dx@uantwerpen.be

Want to change how you receive these emails? You can <u>update your preferences</u> or <u>unsubscribe from this list</u>.

 This email was sent to <<Email Address>>

 why did I get this?
 unsubscribe from this list
 update subscription preferences

 Organisation · Universiteitsplein · Wilrijk 2160 · Belgium